Physician profile
Stuart Spind
NPI 1003843152
$2,908.49
in general payments reported to CMS, 2019-2025
18 companies · $583 in 2025
The $583 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $258 · 2021: $313 · 2022: $552 · 2023: $248 · 2024: $607 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $752.78 | 2019-2025 | Precision 1, Voyager Dslt, Hydrus Microstent |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $400.28 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $321.15 | 2023-2025 | Biotrue One Day, Miebo, Infuse |
| Tarsus Pharmaceuticals, INC. | $250.92 | 2024-2025 | Xdemvy |
| Notal Vision, INC. | $213.69 | 2022 | |
| Coopervision INC. | $199.45 | 2022-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $179.71 | 2019-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $101.92 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $101.08 | 2019-2024 | Cequa |
| Dompe US, INC. | $94.43 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $57.45 | 2021 | |
| Harrow Eye, LLC | $54.87 | 2025 | Vevye |
| Abb Con-Cise Optical Group LLC | $52.82 | 2019 | |
| Lkc Technologies, INC. | $45.45 | 2024 | |
| Allergan, INC. | $33.59 | 2020-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.22 | 2019 | |
| Abbvie INC. | $17.19 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Spind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.